These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 29648686

  • 1. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 3. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M.
    Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
    [Abstract] [Full Text] [Related]

  • 4. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups.
    Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
    [Abstract] [Full Text] [Related]

  • 5. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 6. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.
    Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
    [Abstract] [Full Text] [Related]

  • 7. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 8. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 9. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May 20; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 11. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr 20; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 12. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1143-51. PubMed ID: 19714615
    [Abstract] [Full Text] [Related]

  • 13. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar 15; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 15; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R.
    BioDrugs; 2014 Apr 15; 28(2):211-28. PubMed ID: 24190520
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 15; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
    van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D.
    Rheumatology (Oxford); 2020 Feb 01; 59(2):281-291. PubMed ID: 31302695
    [Abstract] [Full Text] [Related]

  • 18. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.
    Lindblom J, Gomez A, Borg A, Emamikia S, Ladakis D, Matilla J, Pehr M, Cobar F, Enman Y, Heintz E, Regardt M, Parodis I.
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4703-4716. PubMed ID: 33502473
    [Abstract] [Full Text] [Related]

  • 19. Belimumab: in systemic lupus erythematosus.
    Burness CB, McCormack PL.
    Drugs; 2011 Dec 24; 71(18):2435-44. PubMed ID: 22141386
    [Abstract] [Full Text] [Related]

  • 20. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 24; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.